BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) and Hudson Technologies (NASDAQ:HDSN – Get Free Report) are both small-cap industrials companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.
Risk & Volatility
BioNexus Gene Lab has a beta of 4.28, indicating that its stock price is 328% more volatile than the S&P 500. Comparatively, Hudson Technologies has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.
Insider and Institutional Ownership
18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 71.3% of Hudson Technologies shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by company insiders. Comparatively, 1.9% of Hudson Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares BioNexus Gene Lab and Hudson Technologies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioNexus Gene Lab | $7.43 million | 0.34 | -$2.98 million | ($1.26) | -0.69 |
| Hudson Technologies | $242.33 million | 0.77 | $16.67 million | ($0.02) | -222.50 |
Hudson Technologies has higher revenue and earnings than BioNexus Gene Lab. Hudson Technologies is trading at a lower price-to-earnings ratio than BioNexus Gene Lab, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares BioNexus Gene Lab and Hudson Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioNexus Gene Lab | -82.38% | -32.92% | -29.75% |
| Hudson Technologies | -0.54% | 0.80% | 0.61% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for BioNexus Gene Lab and Hudson Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioNexus Gene Lab | 1 | 0 | 0 | 0 | 1.00 |
| Hudson Technologies | 2 | 1 | 2 | 0 | 2.00 |
Hudson Technologies has a consensus target price of $7.00, suggesting a potential upside of 57.30%. Given Hudson Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe Hudson Technologies is more favorable than BioNexus Gene Lab.
Summary
Hudson Technologies beats BioNexus Gene Lab on 12 of the 14 factors compared between the two stocks.
About BioNexus Gene Lab
BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a biotechnology and molecular diagnostics company focused on using genetic and genomic information to support disease screening, risk assessment and personalized healthcare. The company develops and commercializes diagnostic products and laboratory services based on the analysis of biological samples, including blood and other specimens. Its offerings are intended to help identify potential health risks and support the early detection and management of conditions such as cancer and other diseases.
About Hudson Technologies
Hudson Technologies, Inc. (NASDAQ:HDSN) provides refrigerant products and services for the heating, ventilation, air conditioning and refrigeration (HVACR) industry. The company supplies reclaimed and recycled refrigerants, as well as virgin refrigerants and related products, to customers that operate or service commercial, industrial and residential cooling systems. Its services include refrigerant reclamation, refrigerant management, cylinder management, technical support and logistics. Hudson also provides RefrigerantSide Services, which are designed to help customers recover, analyze, replace and manage refrigerants at industrial and commercial facilities.
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.
